Roffeei Siti Norsyuhada, Reynolds Gavin P, Zainal Nor Zuraida, Said Mas Ayu, Hatim Ahmad, Aida Syarinaz Ahmad, Mohamed Zahurin
Pharmacogenomics Laboratory, Department of Pharmacology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Hum Psychopharmacol. 2014 Jan;29(1):38-45. doi: 10.1002/hup.2366. Epub 2013 Nov 25.
Various genetic polymorphisms have been reported to be associated with antipsychotic-induced weight gain. In this study, we aimed to determine whether risk polymorphisms in 12 candidate genes are associated with reduction in body mass index (BMI) of patients following switching of antipsychotics to aripiprazole or ziprasidone.
We recruited 115 schizophrenia patients with metabolic abnormalities and who have been on at least 1 year treatment with other antipsychotics; they were then switched to either aripiprazole or ziprasidone. They were genotyped, and their BMI monitored for 6 months.
Significant associations with reduction in BMI at 6 months following switching were found in two of these genes: with rs1800544 of the ADRA2A gene (CC + CG [-0.32 ± 1.41 kg/m²] vs GG [-1.04 ± 1.63 kg/m²], p = 0.013) and with rs1801131 of the MTHFR gene (AA [-0.36 ± 1.53] vs AC + CC [-1.07 ± 1.53], p = 0.015).
The study data indicated that carriage of the ADRA2A rs1800544 GG genotype and the MTHFR rs1801131 C allele are associated with BMI reduction in this population following switching of antipsychotics to aripiprazole and ziprasidone.
据报道，多种基因多态性与抗精神病药物所致体重增加有关。在本研究中，我们旨在确定12个候选基因中的风险多态性是否与抗精神病药物换用阿立哌唑或齐拉西酮后患者体重指数（BMI）的降低有关。
我们招募了115例患有代谢异常且已接受至少1年其他抗精神病药物治疗的精神分裂症患者；然后将他们换用阿立哌唑或齐拉西酮。对他们进行基因分型，并监测其BMI达6个月。
在这些基因中的两个基因中发现了与换药后6个月时BMI降低的显著关联：ADRA2A基因的rs1800544（CC + CG [-0.32±1.41kg/m²] 对比GG [-1.04±1.63kg/m²]，p = 0.013）以及MTHFR基因的rs1801131（AA [-0.36±1.53] 对比AC + CC [-1.07±1.53]，p = 0.015）。
研究数据表明，在该人群中，抗精神病药物换用阿立哌唑和齐拉西酮后，ADRA2A基因rs1800544的GG基因型携带情况以及MTHFR基因rs1801131的C等位基因与BMI降低有关。
